论文部分内容阅读
目的观察半相合供者细胞因子诱导的杀伤细胞(CIK)治疗晚期肝癌的临床疗效。方法 2例无法手术且无法耐受化疗的晚期肝癌患者分别选取人类白细胞抗原(HLA)半相合健康供者体外培养CIK,14d后分次回输给相应患者,观察患者治疗前后瘤体大小、肿瘤标志物、免疫指标、临床症状、生活质量和卡氏评分等的变化。结果 2例患者治疗后肿瘤标志物甲胎蛋白(AFP)分别下降9835和7000ng/L,临床症状较治疗前有明显改善。结论初步结果显示,HLA半相合供者外周血CIK细胞治疗,能改善晚期肝癌患者症状,并提高生活质量。
Objective To observe the clinical efficacy of haploidentical cytokine-induced killer cells (CIK) in the treatment of advanced liver cancer. Methods Two patients with advanced hepatocellular carcinoma who were unable to undergo surgery and were refractory to chemotherapy were enrolled in this study. Human leukocyte antigen (HLA) haploidentical hematopoietic donors were cultured in vitro for CIK. After 14 days, the CIK cells were infused into the corresponding patients. The tumor size, tumor size Changes in immune indices, clinical symptoms, quality of life, and Karnofsky scores. Results After treatment, the tumor markers AFP dropped by 9835 and 7000 ng / L, respectively. The clinical symptoms were significantly improved after treatment. Conclusions The preliminary results show that treatment of peripheral blood CIK cells in patients with HLA haploidentical donor can improve the symptoms of patients with advanced liver cancer and improve the quality of life.